icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
The Liver Meeting
Boston MA
November 2016
Back grey_arrow_rt.gif
 
 
 
INTERIM ANALYSIS OF A 3-YEAR FOLLOW-UP STUDY OF NS5A AND NS3 RESISTANCE-ASSOCIATED VARIANTS AFTER TREATMENT WITH GRAZOPREVIR-CONTAINING REGIMENS IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS (HCV) INFECTION
 
 
  Reported by Jules Levin
AASLD 2026 Nov 11-15 Boston, MA
 
Frederick Lahser, Angela Galloway, Peggy Hwang, John Palcza, Janice Wahl, Michael Robertson, Eliav Barr, Todd Black, Ernest Asante-Appiah, Barbara Haber Merck & Co., Inc. Kenilworth, NJ, USA

HIV1

HIV2

HIV3

HIV4

HIV5

HIV6

HIV7

HIV8